{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:46:33Z","timestamp":1795088793437,"version":"4.10.2"},"reference-count":33,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide was shown to reduce endothelial cell activation in vitro and is approved in the United States for treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) in patients with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT), and in the European Union for severe VOD\/SOS after HCT in patients aged &amp;gt;1 month. Defibrotide may stabilize the endothelium during CAR-T therapy and reduce the rate of CAR-T\u2013associated neurotoxicity. This phase 2 study evaluated the safety and efficacy of defibrotide for prevention of CAR-T\u2013associated neurotoxicity in patients with relapsed\/refractory large B-cell lymphoma receiving axicabtagene ciloleucel. Part 1 established the recommended phase 2 dose (RP2D; 6.25 mg\/kg); 20 patients (from parts 1 and 2) receiving the RP2D were evaluable for efficacy. Rate of CAR-T\u2013associated neurotoxicity by day 30 (primary end point) was \u223c50%, lower than reported in the ZUMA-1 trial (64%). Median event duration of grade \u22653 neurotoxicity was 7 days. No unexpected defibrotide-related safety findings and defibrotide-related treatment-emergent adverse events or deaths were reported. Results showed modest reduction in rate of CAR-T\u2013associated neurotoxicity and high-grade neurotoxicity event duration relative to historical data; however, reduction was unlikely to\u00a0meet the primary end point, so the study was terminated early. Nevertheless, results\u00a0contribute valuable data for potential therapeutic insight on the management of CAR-T\u2013associated neurotoxicity. This trial was registered at www.clinicaltrials.gov as #NCT03954106.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009961","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T19:14:05Z","timestamp":1688411645000},"page":"6790-6799","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell\u2013associated neurotoxicity syndrome"],"prefix":"10.1182","volume":"7","author":[{"given":"Caron A.","family":"Jacobson","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison C.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Mayo Clinic\u2013Phoenix, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirali","family":"Agarwal","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wu","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vian","family":"Amber","sequence":"additional","affiliation":[{"name":"6Jazz Pharmaceuticals, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2023111416202398200_bib1","article-title":"National Cancer Institute at the National Institutes of Health","year":"2022","journal-title":"CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers"},{"key":"2023111416202398200_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2023111416202398200_bib3","volume-title":"Actemra (tocilizumab). Prescribing information. Genentech, Inc","year":"2010"},{"issue":"1","key":"2023111416202398200_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2023111416202398200_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2023111416202398200_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2023111416202398200_bib7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"14","key":"2023111416202398200_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2023111416202398200_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2023111416202398200_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023111416202398200_bib11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2023111416202398200_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2023111416202398200_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"2023111416202398200_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023111416202398200_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2023111416202398200_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"2023111416202398200_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2023111416202398200_bib18","article-title":"Defitelio. Summary of Product Characteristics","year":"2019","journal-title":"Defitelio"},{"key":"2023111416202398200_bib19","article-title":"Defitelio. 80\u00a0mg\/mL Summary of Product Characteristics EU","year":"2016","journal-title":"Gentium SRL"},{"issue":"12","key":"2023111416202398200_bib20","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/s41409-021-01383-x","article-title":"The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae","volume":"56","author":"Richardson","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2023111416202398200_bib21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2015-10-676114","article-title":"What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance","volume":"127","author":"Palomo","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023111416202398200_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","article-title":"Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation","volume":"17","author":"Palomo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1-2","key":"2023111416202398200_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"2023111416202398200_bib24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2023111416202398200_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2023111416202398200_bib26","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023111416202398200_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"16","key":"2023111416202398200_bib28","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon's two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat Med"},{"key":"2023111416202398200_bib29","article-title":"BLA Clinical Review Memorandum \u2013 YESCARTA","year":"2017","journal-title":"FDA"},{"issue":"2","key":"2023111416202398200_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1116","key":"2023111416202398200_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/postgradmedj-2018-135815","article-title":"A\u00a0long wait: barriers to discharge for long length of stay patients","volume":"94","author":"Zhao","year":"2018","journal-title":"Postgrad Med J"},{"issue":"3","key":"2023111416202398200_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2023111416202398200_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6790\/2089005\/blooda_adv-2023-009961-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6790\/2089005\/blooda_adv-2023-009961-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T16:21:14Z","timestamp":1699978874000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6790\/496695\/A-phase-2-trial-of-defibrotide-for-the-prevention"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009961","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}